Strengthen our positioning as a specialist further developing new immunodiagnostics and molecular diagnostics products leveraging on the complete offer of automated proprietary analyzers on both technologies.
Consolidate the leading positioning in the immunodiagnostics leveraging the breadth of our CLIA product portfolio and further develop new specialty tests.
Commercial clients base
Physician Office Labs
Class III Hospitals
Class II Hospitals
New products launches to enlarge the menu adding to the LIAISON MDX platform (currently used to serve central hospital laboratories) a new Point of Care molecular platform.
Expand offer with 5/6 new tests yearly: